Introducing SmithRx’s Low-Cost Insulin Program

**An update on our low-cost insulin program.**

Diabetes is commonly among the highest drug spend categories for employer groups.

SmithRx is forging new pathways to make insulin more affordable. Starting July 1, 2023, biosimilar insulin products manufactured by Lilly will be preferred on the SmithRx formularies. In the SmithRx pass-through model, all the savings from filling biosimilar insulins are passed along to the employer group. 

Lilly is Humalog's manufacturer and also manufactures lower-cost alternatives (i.e. Insulin Lispro) that are interchangeable with the brand products. The SmithRx Low Cost Insulin Program decreases the cost of insulin at the pharmacy for employer groups and applies a savings card to reduce member copays to $35 or less for a 30 day supply for Lilly insulin products. Through this program, the cost of insulin is less than the member’s standard copay or $35 for a month’s supply.

The lowest cost insulin for mealtime is Insulin Lispro 100 units/mL (biosimilar for Humalog) and long-acting once daily is Rezvoglar (biosimilar for Lantus). These lower cost biosimilar insulins can be filled at any pharmacy within the SmithRx network.

Interested in learning more about how your clients can benefit from SmithRx's Low Cost Insulin or our other Connect 360 programs?  Get in touch!

Already a SmithRx client and want to learn more?  Our Account Managers are happy to hear from you.